ScholarIQanswers from OpenAlex & ORCID
Nancy U. Lin
ResearcherPublications, citations & collaboration network
Nancy U. Lin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nancy U. Lin have?
ScholarIQindexed works
Nancy U. Lin has 1,053 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nancy U. Lin have?
ScholarIQcitation count
Nancy U. Lin has 43,587 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nancy U. Lin?
ScholarIQh-index
Nancy U. Lin has an h-index of 96 in OpenAlex.
What is the i10-index of Nancy U. Lin?
ScholarIQi10-index
Nancy U. Lin has an i10-index of 288 in OpenAlex.
What is the ORCID of Nancy U. Lin?
ScholarIQorcid
The ORCID for Nancy U. Lin is on the source record.
What is the OpenAlex record for Nancy U. Lin?
ScholarIQopenalex
The OpenAlex for Nancy U. Lin is on the source record.
What are the most-cited papers on Nancy U. Lin?
ScholarIQmost cited works
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer
A pathology foundation model for cancer diagnosis and prognosis prediction
Xiyue Wang, Junhan Zhao, Eliana Marostica, Wei Yuan, Jietian Jin, Jiayu Zhang, Ruijiang Li, Hongping Tang, Kanran Wang, Yu Li, Fang Wang, Yulong Peng, Junyou Zhu, Jing Zhang, Christopher Jackson, Jun Zhang, Deborah Dillon, Nancy U. Lin, Lynette M. Sholl, Thomas Denize, David M. Meredith, Keith L. Ligon, Sabina Signoretti, Shuji Ogino, Jeffrey A. Golden, MacLean P. Nasrallah, Xiao Han, Sen Yang, Kun‐Hsing Yu
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Bob T. Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai‐Yan Tu, Mackenzie L. Myers, Chong‐Rui Xu, Marissa S. Mattar, Inna Khodos, Megan Little, Besnik Qeriqi, Gregory Weitsman, Clare J. Wilhem, Alshad S. Lalani, Irmina Diala, Rachel A. Freedman, Nancy U. Lin, David B. Solit, Michael F. Berger, Paul R. Barber, Tony Ng, Michael Offin, James M. Isbell, David R. Jones, Helena A. Yu, Sheeno Thyparambil, Wei‐Li Liao, Anuja Bhalkikar, Fabiola Cecchi, David M. Hyman, Jason S. Lewis, Darren J. Buonocore, Alan L. Ho, Vicky Makker, Jorge S. Reis‐Filho, Pedram Razavi, Maria E. Arcila, Mark G. Kris, John T. Poirier, Ronglai Shen, Junji Tsurutani, Gary A. Ulaner, Elisa de Stanchina, Neal Rosen, Charles M. Rudin, Maurizio Scaltriti
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, PierFranco Conte, Véronique Dièras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders